The CONMED Corporation is a publicly traded American manufacturer of medical equipment and surgical devices, primarily in the orthopedic, laparoscopic and general surgery, and patient care areas. CONMED's headquarters is in Largo, Florida. Prior to July 2022, it was in Utica, New York.3 Its shares trade on NYSE under the symbol CNMD.1Wikipedia text CC BY-SA 4.0
The CONMED Corporation is a publicly traded American manufacturer of medical equipment and surgical devices, primarily in the orthopedic, laparoscopic and general surgery, and patient care areas. CONMED's headquarters is in Largo, Florida. Prior to July 2022, it was in Utica, New York. CONMED embraces a people-first culture that starts with a mission to support their healthcare partners and the patients they serve. They have manufacturing facilities in the United States and Mexico, offices internationally, and a vast global footprint.3
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Revenue91011128$1.4B in 2025+44% since 2019Gross profit91011128$750.5M in 2025+43% since 2019Operating income91011128$102.6M in 2025+30% since 2019Net income91011128$47.1M in 2025+64% since 2019
Revenue1314$343.5M in Q2 FY2026+2% since Q3 FY2025Gross profit1314$197.5M in Q2 FY2026+19% since Q3 FY2025Operating income1314$36.4M in Q2 FY2026+206% since Q3 FY2025Net income1314$23.1M in Q2 FY2026+707% since Q3 FY2025
Every line of the income statement as filed: the last 3 fiscal years, latest first.8
Period ending
2025-12-31
2024-12-31
2023-12-31
Net sales
$1.4B
$1.3B
$1.2B
Cost of sales
$624.2M
$574.0M
$568.5M
Gross profit
$750.5M
$733.0M
$676.2M
Selling and administrative expense
$592.0M
$478.3M
$503.0M
Research and development expense
$55.9M
$54.4M
$52.6M
Operating expenses
$647.9M
$532.7M
$555.6M
Income from operations
$102.6M
$200.3M
$120.6M
Interest expense
$31.1M
$37.3M
$39.8M
Other expense
$418.0K
$0
$0
Income before income taxes
$71.1M
$163.0M
$80.8M
Provision for income taxes
$24.1M
$30.6M
$16.4M
Net income
$47.1M
$132.4M
$64.5M
Basic (in dollars per share)
$1.52
$4.29
$2.10
Diluted (in dollars per share)
$1.51
$4.25
$2.04
Cash flow hedging
-$6.9M
$5.5M
-$3.1M
Pension liability
$3.4M
$2.5M
$6.6M
Foreign currency translation adjustments
$15.2M
-$14.8M
$5.1M
Other comprehensive income (loss), before income tax
$11.7M
-$6.7M
$8.5M
Provision (benefit) for income taxes related to items in other comprehensive income (loss)
-$834.0K
$1.9M
$832.0K
Other comprehensive income (loss), net of income tax
$12.6M
-$8.7M
$7.7M
Comprehensive income
$59.6M
$123.7M
$72.1M
No quarter-by-quarter statement was filed.
Total assets1591011128$2.3B in 2025+31% since 2019Total liabilities1591011128$1.3B in 2025+21% since 2019Shareholders’ equity1011128$1.0B in 2025+45% since 2019Cash1611128$40.8M in 2025+58% since 2019
Total assets1314$2.3B in Q2 FY2026−1% since Q3 FY2025Total liabilities1314$1.3B in Q2 FY2026−4% since Q3 FY2025Shareholders’ equity1314$1.0B in Q2 FY2026+4% since Q3 FY2025Cash1314$37.3M in Q2 FY2026−4% since Q3 FY2025
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.8
Period ending
2025-12-31
2024-12-31
2023-12-31
2022-12-31
Cash and cash equivalents
$40.8M
$24.5M
$24.3M
$28.9M
Accounts receivable, less allowance for doubtful accounts of $6,300 in 2025 and $5,739 in 2024
$247.8M
$237.7M
Inventories
$355.5M
$346.7M
Prepaid expenses and other current assets
$28.7M
$31.1M
Total current assets
$672.9M
$640.0M
Property, plant and equipment, net
$113.3M
$115.8M
Deferred income taxes
$13.3M
$11.1M
Goodwill
$807.0M
$805.4M
$806.8M
Other intangible assets, net
$582.1M
$617.7M
Other assets
$137.2M
$116.4M
Total assets
$2.3B
$2.3B
Current portion of long-term debt
$712.0K
$715.0K
Accounts payable
$93.6M
$102.2M
Accrued compensation and benefits
$82.1M
$65.4M
Other current liabilities
$138.5M
$109.8M
Total current liabilities
$315.0M
$278.1M
Long-term debt
$834.2M
$905.1M
Deferred income taxes
$79.5M
$74.1M
Other long-term liabilities
$63.9M
$86.3M
Total liabilities
$1.3B
$1.3B
Preferred stock, par value $.01 per share; authorized 500,000 shares, none issued or outstanding
$0
$0
Common stock, par value $.01 per share; 100,000,000 authorized; 31,299,194 issued in 2025 and 2024, respectively
$313.0K
$313.0K
Paid-in capital
$503.2M
$476.6M
Retained earnings
$588.8M
$560.3M
Accumulated other comprehensive loss
-$46.3M
-$58.9M
Less: Treasury stock, at cost; 328,097 and 397,860 shares in 2025 and 2024, respectively
-$12.9M
-$15.6M
Total shareholders' equity
$1.0B
$962.7M
$834.2M
$745.5M
Total liabilities and shareholders' equity
$2.3B
$2.3B
Allowance for doubtful accounts
$6.3M
$5.7M
Preferred stock, par value (in dollars per share)
$0.01
$0.01
Preferred stock, shares authorized (in shares)
500.0K shares
500.0K shares
Preferred stock, shares issued (in shares)
0 shares
0 shares
Preferred stock, shares outstanding (in shares)
0 shares
0 shares
Common stock, par value (in dollars per share)
$0.01
$0.01
Common stock, shares authorized (in shares)
100.0M shares
100.0M shares
Common stock, shares issued (in shares)
31.3M shares
31.3M shares
Treasury stock, common shares (in shares)
328.1K shares
397.9K shares
Period ending
2025-12-31
2024-12-31
2023-12-31
2022-12-31
Cash and cash equivalents
$40.8M
$24.5M
$24.3M
$28.9M
Accounts receivable, less allowance for doubtful accounts of $6,300 in 2025 and $5,739 in 2024
$247.8M
$237.7M
Inventories
$355.5M
$346.7M
Prepaid expenses and other current assets
$28.7M
$31.1M
Total current assets
$672.9M
$640.0M
Property, plant and equipment, net
$113.3M
$115.8M
Deferred income taxes
$13.3M
$11.1M
Goodwill
$807.0M
$805.4M
$806.8M
Other intangible assets, net
$582.1M
$617.7M
Other assets
$137.2M
$116.4M
Total assets
$2.3B
$2.3B
Current portion of long-term debt
$712.0K
$715.0K
Accounts payable
$93.6M
$102.2M
Accrued compensation and benefits
$82.1M
$65.4M
Other current liabilities
$138.5M
$109.8M
Total current liabilities
$315.0M
$278.1M
Long-term debt
$834.2M
$905.1M
Deferred income taxes
$79.5M
$74.1M
Other long-term liabilities
$63.9M
$86.3M
Total liabilities
$1.3B
$1.3B
Preferred stock, par value $.01 per share; authorized 500,000 shares, none issued or outstanding
$0
$0
Common stock, par value $.01 per share; 100,000,000 authorized; 31,299,194 issued in 2025 and 2024, respectively
$313.0K
$313.0K
Paid-in capital
$503.2M
$476.6M
Retained earnings
$588.8M
$560.3M
Accumulated other comprehensive loss
-$46.3M
-$58.9M
Less: Treasury stock, at cost; 328,097 and 397,860 shares in 2025 and 2024, respectively
-$12.9M
-$15.6M
Total shareholders' equity
$1.0B
$962.7M
$834.2M
$745.5M
Total liabilities and shareholders' equity
$2.3B
$2.3B
Allowance for doubtful accounts
$6.3M
$5.7M
Preferred stock, par value (in dollars per share)
$0.01
$0.01
Preferred stock, shares authorized (in shares)
500.0K shares
500.0K shares
Preferred stock, shares issued (in shares)
0 shares
0 shares
Preferred stock, shares outstanding (in shares)
0 shares
0 shares
Common stock, par value (in dollars per share)
$0.01
$0.01
Common stock, shares authorized (in shares)
100.0M shares
100.0M shares
Common stock, shares issued (in shares)
31.3M shares
31.3M shares
Treasury stock, common shares (in shares)
328.1K shares
397.9K shares
Cash from operations91011128$170.7M in 2025+79% since 2019Capital spending91011128$19.8M in 2025−1% since 2019Free cash flow91011128$150.9M in 2025+101% since 2019Dividends paid91011128$24.7M in 2025+9% since 2019
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.8
Period ending
2025-12-31
2024-12-31
2023-12-31
Net income
$47.1M
$132.4M
$64.5M
Depreciation
$17.1M
$16.6M
$16.2M
Amortization of deferred debt issuance costs
$5.6M
$5.7M
$6.1M
Amortization
$57.1M
$55.3M
$55.7M
Stock-based compensation
$28.3M
$25.6M
$24.3M
Deferred income taxes
$3.5M
$12.2M
$700.0K
Changes in fair value of contingent consideration
$23.0M
-$41.0M
-$2.4M
Loss on early extinguishment of debt
$363.0K
$0
$0
Accounts receivable
-$2.4M
-$1.6M
-$47.1M
Inventories
-$6.7M
-$31.6M
$14.1M
Accounts payable
-$9.7M
$14.7M
$14.8M
Income taxes
-$558.0K
-$193.0K
-$3.9M
Accrued compensation and benefits
$14.9M
-$2.8M
$14.4M
Other assets
-$13.2M
-$13.9M
-$21.8M
Other liabilities
$6.2M
-$4.2M
-$10.1M
Net cash provided by operating activities
$170.7M
$167.0M
$125.3M
Purchases of property, plant and equipment
-$19.8M
-$13.1M
-$19.0M
Other
-$1.1M
$0
-$1.0M
Net cash used in investing activities
-$21.0M
-$13.1M
-$20.0M
Payments on term loan
-$99.8M
$0
-$20.0M
Proceeds from term loan
$25.2M
$0
$0
Payments on revolving line of credit
-$695.4M
-$753.0M
-$760.0M
Proceeds from revolving line of credit
$695.4M
$751.0M
$692.0M
Payments to redeem convertible notes
$0
-$70.0M
$0
Payments related to contingent consideration
-$33.8M
-$56.9M
-$13.9M
Payments related to debt issuance costs
-$2.9M
-$303.0K
$0
Dividends paid on common stock
-$24.7M
-$24.7M
-$24.5M
Other, net
$170.0K
$2.8M
$15.9M
Net cash used in financing activities
-$135.8M
-$151.0M
-$110.4M
Effect of exchange rate changes on cash and cash equivalents
$2.4M
-$2.7M
$470.0K
Net increase (decrease) in cash and cash equivalents
CONMED Corporation sits at the top of its group. 37 entities, 21 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
CONMED CorporationNew York, New York, United States
Aspen Laboratories, Inc. Subsidiary · Colorado, United States
Biorez Pty Ltd Subsidiary · Australia
Buffalo Filter LLC Subsidiary · Delaware, United States
CONMED Andover Medical, Inc. Subsidiary · New York, United States
CONMED Austria GmbH Subsidiary · Austria
CONMED Denmark ApS Subsidiary · Denmark
CONMED Deutschland GmbH Subsidiary · Germany
Conmed do Brasil Comércio Importação e Exportação de Produtos Médicos Hospitalares Ltda. Subsidiary · Brazil
CONMED Endoscopic Technologies, Inc. Subsidiary · Massachusetts, United States
CONMED EUROPE Subsidiary · Drogenbos, Belgium
CONMED LINVATEC AUSTRALIA PTY LTD Subsidiary · Utica, New York, United States
CONMED Finland Oy Subsidiary · Finland
CONMED France SAS Subsidiary · France
CONMED Iberia SL Subsidiary · Spain
CONMED Italia SrL Subsidiary · Italy
CONMED Japan K. K. Subsidiary · Japan
CONMED Linvatec (Beijing) Medical Appliances Co., Ltd Subsidiary · China
CONMED Linvatec Australia PTY Ltd Subsidiary · Australia
CONMED Switzerland GmbH Subsidiary · Switzerland
CONMED U.K. Ltd. Subsidiary · United Kingdom
Consolidated Medical Equipment Company S. de R.L. de C.V. Subsidiary · Mexico
EndoDynamix, Inc. Subsidiary · Delaware, United States
GWH Limited Partnership Subsidiary · Florida, United States
In2Bones Global, Inc. Subsidiary · Delaware, United States
In2Bones SAS Subsidiary · France
Largo Lakes I Limited Partnership Subsidiary · Delaware, United States
and 10 more
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What CONMED Corporation reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
The following table sets forth certain information with respect to our principal operating facilities. We believe that our facilities are generally well maintained, are suitable to support our business and adequate for present and anticipated needs.
The rest of Item 2
Location · Square Feet · Own or Lease · Lease Expiration
Utica, NY · 500,000 · Own · —
Largo, FL · 278,000 · Own · —
Lithia Springs, GA · 330,000 · Lease · September 2034
Chihuahua, Mexico · 207,720 · Lease · October 2029
Greenwood Village, CO · 50,405 · Lease · May 2036
Chihuahua, Mexico · 40,626 · Lease · March 2028
Brussels, Belgium · 58,276 · Lease · June 2030
Mississauga, Canada · 36,054 · Lease · July 2036
Cordova, TN · 26,110 · Lease · April 2032
Our principal manufacturing facilities are located in Utica, NY, Largo, FL and Chihuahua, Mexico. Lithia Springs, GA and Brussels, Belgium are our principal distribution centers. We also maintain sales and administrative offices in countries throughout the world.
In 1970, Eugene Corasanti (1930–2015) purchased a small medical supplied distributor in Utica, New York. He originally named the company Concor Enterprises, but later renamed it to Consolidated Medical Equipment, Inc. Its first product was a disposable ECG electrode. Growing through acquisitions, Corasanti served as CEO until 2006 when Curt Hartman gained the President, CEO, and Chairman of the Board position in 2014. Pat Beyer took over as President and CEO on January 1, 2025.
Oct 30, 2024Reported quarterly or annual results99
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
395 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 66 major events, 227 insider forms, 25 large holders, 57 other. The latest 20:
49 open-market trades by officers, directors and large owners since October 2021: 4 buys and 45 sales. Grants, option exercises and gifts are left out.
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How CONMED Corporation is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
From the cover page of the 10-K filed Feb 17, 2026 (Section 12(b) of the Exchange Act).17
Risk factors and legal proceedings
The risks CONMED Corporation names in Item 1A of its 10-K filed Feb 17, 2026: 39 risks under these headings, as written.17
(i) Risks Related to Our Business and the Medical Device Industry
Our financial performance is dependent on conditions in the healthcare industry and the broader economy. Our business and financial performance could be adversely affected, directly or indirectly, by a potential economic downturn.
Limitations on the availability of Ethylene Oxide (“EtO”) sterilization services may limit our ability to sell certain sterile products.
As a medical device manufacturer that interacts with physicians and healthcare providers domestically and internationally, we face risks under domestic and foreign laws and regulations, including anti-bribery, anti-corruption, and false claims laws, globally, and could face substantial penalties if we fail to comply with such regulations and laws.
We are subject to various U.S. federal, state and foreign healthcare laws and regulations, which could increase compliance costs, and our failure to comply with these laws and regulations could harm our reputation, subject us to significant fines and liability or otherwise adversely affect our business.
Failure to comply with regulatory requirements may result in recalls, loss of revenues, fines or other materially adverse implications.
Disruptions at the FDA and other government agencies caused by funding shortages, staffing limitations, or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, prevent new or modified products from being developed, reviewed, approved or commercialized in a timely manner or at all, which could negatively impact our business.
The highly competitive market for our products may create adverse pricing pressures.
If third-party payors decline to reimburse our customers for our products or reduce reimbursement levels, the demand for our products may decline and our ability to sell our products profitably may be harmed.
Cost reduction efforts in the healthcare industry could put pressures on our prices and margins.
With a global footprint and supply chain, our results and operations could be adversely affected by raw material shortages, inflation, price increases, economic or geopolitical developments, including protectionist trade policies such as tariffs, or other events.
We may not be able to keep pace with technological change or to successfully develop new products with wide market acceptance, which could cause us to lose business to competitors.
The other 27 risks
Ordering patterns of our customers may change resulting in reductions in sales.
(ii) Risks Related to Our Indebtedness
The terms of our indebtedness outstanding from time to time, including our senior credit agreement, may restrict our current and future operations, particularly our ability to respond to changes or to take certain actions.
We may not be able to generate sufficient cash to service our indebtedness and other obligations, and, our leverage and debt service requirements may require us to adopt alternative business strategies.
Our variable rate indebtedness subjects us to interest rate risk, which could cause our debt service obligations to increase significantly.
Despite our current level of indebtedness, we and our subsidiaries may still be able to incur substantially more debt. This could further exacerbate the risks to our financial condition described above.
The conditional conversion features of our 2.250% Notes if triggered, may adversely affect our financial condition.
The convertible notes hedge and warrant transactions that we entered into in connection with the offering of the Convertible Notes may affect the value of the Convertible Notes and our common stock.
We are subject to counterparty risk with respect to the convertible notes hedge transactions.
The terms of any future preferred equity or debt financing may give holders of any preferred securities or debt securities rights that are senior to rights of our common shareholders or impose more stringent operating restrictions on our company.
(iii) Risks Related to Our Strategic Transactions
Our financial performance is subject to the risks inherent in any acquisition, including the effects of increased borrowing and integration of newly acquired businesses or product lines.
Our financial performance is subject to risks in connection with divestitures, and our failure to manage these divestitures could have a negative impact on our business.
(iv) Other Risks Related to Our Business
We could experience a failure of a key information technology system, process or site or a breach of information security, including a cybersecurity breach or failure of one or more key information technology systems, networks, processes, associated sites or service providers, and could potentially become liable for a breach of various data privacy regulations.
We rely on various software programs and information technology systems to run our business, some of which may be old or no longer supported and requiring replacements or updates. The failure of any of these software systems or information technology systems to operate properly, or disruptions associated with updating or implementing new software or information technology systems, may have a material adverse effect on our business, financial condition or results of operations.
Our use of artificial intelligence (“AI”) and other emerging technologies could adversely impact our business and financial results.
We rely on a third party to obtain, process and distribute sports medicine allograft tissue. If such tissue cannot be obtained, is not accepted by the market or is not compliant with applicable government regulations, our results of operations could be negatively impacted.
We distribute some products for third-party companies, and cannot ensure that our rights to distribute such third-party products will continue indefinitely.
If we lose our patents or they are held to be invalid, or if our products or services infringe on third party patents, we could become subject to liability and our competitive position could be harmed.
We may be sued for product liability claims and our insurance coverage may be insufficient to cover the nature and amount of any product liability claims.
Our business may be damaged or disrupted as a result of natural or man-made disasters, or public health crises.
Our insurance coverage is limited to certain caps, and our insurance may not be adequate to cover future losses.
Our significant international operations subject us to foreign currency fluctuations and other risks associated with operating in countries outside the U.S.
Our new products may fail to achieve expected levels of market acceptance.
Our Board of Directors may, in the future, not approve payment of a dividend on common stock.
Anti-takeover provisions in our organizational documents and Delaware law could delay or prevent a change in control.
Violations of environmental, social and governance laws and regulations and climate change initiatives could materially and adversely affect our business, financial condition, and results of operations.
Our ability to attract and retain qualified employees is critical to our success.
Legal proceedings
We are involved in various proceedings, legal actions and claims arising in the normal course of business, including proceedings related to product, labor and intellectual property and other matters that are more fully described in Note 13. We are not a party to any pending legal proceedings other than ordinary routine litigation incidental to our business.
